Investment Analysts’ Weekly Ratings Updates for Vera Therapeutics (VERA)

A number of firms have modified their ratings and price targets on shares of Vera Therapeutics (NASDAQ: VERA) recently:

• 10/26/2026 – Vera Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 10/23/2026 – Vera Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/15/2026 – Vera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Vera Therapeutics is now covered by Leerink Partners. They set a “market perform” rating and a $34.00 price target on the stock.
• 9/15/2026 – Vera Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 9/15/2026 – Vera Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 9/8/2026 – Vera Therapeutics had its price target raised by JPMorgan Chase & Co. from $76.00 to $83.00. They now have an “overweight” rating on the stock.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at $8,704,028. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by insiders.

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.